RightFit
RecruitingPhase not listed

Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
45 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

  • Procedures mentioned: MRI scans, Questionnaires

Only what the study's summary and detailed description on ClinicalTrials.gov say. Time periods may describe the whole study or a part of it — ask the study team what applies to you.

Show the study's own words
  • "Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires."
Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study compares brain chemicals in people with Parkinson’s disease who have an LRRK2 gene change and those who do not. It looks at how these chemicals relate to movement and thinking, using brain scans, tests, and questionnaires. The listed entry rules are for adults age 45 or older with Parkinson’s disease and a confirmed LRRK2 gene change.

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Age 45 or older, male or female.
  • Have Parkinson’s disease diagnosed using the study’s required medical standards.
  • Have a confirmed LRRK2 gene change, shown through a clinic referral, medical records, or the PDGENEration study.

Who can't join

  • Have signs of a condition that looks like Parkinson’s disease but is a different illness.
  • Cannot safely have an MRI brain scan, for example because of certain implants, metal in the eye, or a severe fear of tight spaces.
  • An MRI shows a stroke in a large blood vessel or a mass in the brain.
  • Regularly take anticholinergic drugs or cholinesterase inhibitors, medicines that affect a brain chemical called acetylcholine.
  • Have had surgery for deep brain stimulation, or are pregnant or breastfeeding.
  • Have thoughts of suicide that meet the study’s cutoff on a depression questionnaire.
  • Have thinking problems that make you unable to give consent, as shown by a decision-making test.
  • Have another condition that makes taking part unsafe or prevents meaningful participation.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: 1. Male or Female, age 45 years and over. 2. Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992). 3. Presence of LRRK2 mutation as confirmed by referral from UM Movement Disorders clinic, medical record review, or participation in the PDGENEration study. Exclusion Criteria: 1. Evidence of atypical parkinsonism. 2. Contra-indications to MR imaging including but not limited to pacemakers, aneurysm clips, intraocular metal, cochlear implant, or severe claustrophobia. 3. Evidence of large vessel stroke or mass lesion on MRI. 4. Regular use of typical anti-cholinergic drugs or cholinesterase inhibitors. 5. History of deep brain stimulation surgery. 6. Pregnant or nursing. 7. Suicidal ideation, as indicated by a response of 2 or 3 on question 9 of the Beck Depression Inventory. 8. Cognitive impairment that results in the inability to give consent, as demonstrated by the Decision Making Capacity Tool. 9. Any other condition or criterion that would preclude safe and meaningful participation in the study.

Study sites (1)

MI